AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.